Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third dose of mRNA-1273 (Moderna) in kidney transplant recipients with initial immunological failure to COVID-19 vaccination
2021-002356-37Phase 2Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Sep 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoints: Development of cellular and humoral immunity after third mRNA-1273 dose and Cellular and humoral immunity at 4 months. Started Sep 2021; status: terminated.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-002356-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002356-37.